Literature DB >> 17991925

International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience.

Andrew Bottomley1, Neil K Aaronson.   

Abstract

Over recent decades, health-related quality of life (HRQOL) research has been increasingly integrated into cancer clinical trials. The purpose of this review is to examine the overall approach taken towards clinical trial-based HRQOL investigations within the European Organisation for Research and Treatment of Cancer (EORTC). This article reports a literature review of clinical trial-based HRQOL investigations and provides selective examples of HRQOL studies in phase III clinical trials in various disease sites. The findings of this review highlight that, historically, assessing HRQOL was a challenge. However, as EORTC has become more experienced in the assessment of HRQOL and has developed a portfolio of appropriate tools, HRQOL has become a more accepted end point in large-scale trials. The trials reviewed in this article show that, in general, HRQOL data do provide information that can both inform clinicians about the effectiveness of the treatments and also serve as an invaluable source of information for patients to make informed decisions regarding the treatment choice.

Entities:  

Mesh:

Year:  2007        PMID: 17991925     DOI: 10.1200/JCO.2007.11.3183

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.

Authors:  Eun-ju Kim; Su-Kyoung Ko; Hye-Young Kang
Journal:  Qual Life Res       Date:  2011-10-20       Impact factor: 4.147

2.  Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.

Authors:  Anamaria R Yeung; Stephanie L Pugh; Ann H Klopp; Karen M Gil; Lari Wenzel; Shannon N Westin; David K Gaffney; William Small; Spencer Thompson; Desiree E Doncals; Guilherme H C Cantuaria; Brian P Yaremko; Amy Chang; Vijayananda Kundapur; Dasarahally S Mohan; Michael L Haas; Yong Bae Kim; Catherine L Ferguson; Snehal Deshmukh; Deborah W Bruner; Lisa A Kachnic
Journal:  J Clin Oncol       Date:  2020-02-19       Impact factor: 44.544

3.  When using patient-reported outcomes in clinical practice, the measure matters: a randomized controlled trial.

Authors:  Claire F Snyder; Joseph M Herman; Sharon M White; Brandon S Luber; Amanda L Blackford; Michael A Carducci; Albert W Wu
Journal:  J Oncol Pract       Date:  2014-07-01       Impact factor: 3.840

Review 4.  Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials.

Authors:  Krzysztof Adamowicz
Journal:  Qual Life Res       Date:  2016-10-13       Impact factor: 4.147

5.  Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders.

Authors:  Stephen T Tiffany; Lawrence Friedman; Shelly F Greenfield; Deborah S Hasin; Ron Jackson
Journal:  Addiction       Date:  2011-10-07       Impact factor: 6.526

6.  Enhancing patient-reported outcome measurement in research and practice of palliative and end-of-life care.

Authors:  Steffen T Simon; Irene J Higginson; Richard Harding; Barbara A Daveson; Marjolein Gysels; Luc Deliens; Michael A Echteld; Lukas Radbruch; Franco Toscani; Dominik M Krzyzanowski; Massimo Costantini; Julia Downing; Pedro L Ferreira; Abdelhamid Benalia; Claudia Bausewein
Journal:  Support Care Cancer       Date:  2012-03-07       Impact factor: 3.603

Review 7.  Quality of Life Measurements: Any Value for Clinical Practice?

Authors:  Matthias Büttner; Veit Zebralla; Andreas Dietz; Susanne Singer
Journal:  Curr Treat Options Oncol       Date:  2017-05

8.  Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia.

Authors:  Chris L Pashos; Christopher R Flowers; Neil E Kay; Mark Weiss; Nicole Lamanna; Charles Farber; Susan Lerner; Jeff Sharman; David Grinblatt; Ian W Flinn; Mark Kozloff; Arlene S Swern; Thomas K Street; Kristen A Sullivan; Gale Harding; Zeba M Khan
Journal:  Support Care Cancer       Date:  2013-06-08       Impact factor: 3.603

Review 9.  Measuring outcomes in oncology treatment: the importance of patient-centered outcomes.

Authors:  Aundrea Oliver; Caprice C Greenberg
Journal:  Surg Clin North Am       Date:  2009-02       Impact factor: 2.741

10.  Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes.

Authors:  Aisha S Sie; Judith B Prins; Liesbeth Spruijt; C Marleen Kets; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.